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:   human protein atlas
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:   urogenital

Screening of human urinary proteome for disease biomarkers is a subject of attractions in clinical proteomics [1](#pmic12160-bib-0001){ref-type="ref"}, [2](#pmic12160-bib-0002){ref-type="ref"}, [3](#pmic12160-bib-0003){ref-type="ref"}, [4](#pmic12160-bib-0004){ref-type="ref"}. Besides sampling simplicity and relative stability to other biofluids, urine proteome analysis is preferred over other complex biofluids (serum or plasma) because it is less complex especially when targeting protein/peptide biomarkers [5](#pmic12160-bib-0005){ref-type="ref"}, [6](#pmic12160-bib-0006){ref-type="ref"}. As a regular excretory process, urine is produced in the kidneys, to eliminate plasma wastes, and passed through a 25--30 cm long tube "ureters" to be stored in the urinary bladder [1](#pmic12160-bib-0001){ref-type="ref"}. During this process, more than 90% of the "initial" urine is reabsorbed [1](#pmic12160-bib-0001){ref-type="ref"}. The remaining "final" urine contains not only wasted molecules but also some protein molecules originated from urogenital (UG) tract and plasma as well. Theoretically, urinary proteins might be originated from renal tubular secretion of soluble proteins, sloughed cells of UG tract, glycosylphosphatidylinositol‐anchored protein detachment (such as uromodulin), membranous/cytosolic exosomal proteins, or glomerular‐filtrated plasma proteins [7](#pmic12160-bib-0007){ref-type="ref"}, [8](#pmic12160-bib-0008){ref-type="ref"}. It was reported that in a normal healthy individual, 70% of urinary proteome are originated from the UG tract, while remaining 30% are plasma proteins filtered by the glomerulus [1](#pmic12160-bib-0001){ref-type="ref"}. Although several studies have been published describing the potential uses of urine proteome and peptidome in some UG diseases (acute transplant rejection [9](#pmic12160-bib-0009){ref-type="ref"}, UG tract infection [10](#pmic12160-bib-0010){ref-type="ref"}, chronic kidney disease [11](#pmic12160-bib-0011){ref-type="ref"}, cancer [12](#pmic12160-bib-0012){ref-type="ref"}), little is known regarding where these protein molecules originated from. More specifically within UG tract, if these proteins originated from the kidneys, ureter, or urinary bladder.

To disclose this fundamental question, we attempted to analyze the ureter proteome. Then, we proposed that some of these proteins might be released in urine during its passage within the ureter as entrained exosomes or as a process of urothelium turnover. In order to confirm the validity of our assumption, we compared ureter proteome with a comprehensive mass spectrometric urinary database, exosomal urinary database, and kidney database. Retained protein hits to ureter were further compared to urinary bladder and prostate databases from human protein atlas (HPA) \[[13](#pmic12160-bib-0013){ref-type="ref"}\].

Normal healthy ureter sample (4--5 cm in length) was dissected from diseased kidney and obtained from individuals with informed consent and under the approval of Committee of Ethics for Life and Genes of the Graduate School of Medical and Dental Sciences, Niigata University. Protein extracts were obtained by placing dissected ureter tissues in protein OFFGel prefractionation buffer supplied by the manufacturer (containing urea, thiourea, DTT, glycerol, and buffer with ampholytes pH \[3--10\]) [14](#pmic12160-bib-0014){ref-type="ref"}, [15](#pmic12160-bib-0015){ref-type="ref"}, [16](#pmic12160-bib-0016){ref-type="ref"}. Complete ultraproteases (Roche, Mannheim, Germany) were added to the buffer. Precellys 24 tissue homogenizer was used for protein extraction at 4°C (Precellys, Bertin Technologies). Two milligram of recovered protein extract was subjected to OFFGel fractionation using 3100 OFFGel fractionator (Agilent Technologies, Japan) as previously described [14](#pmic12160-bib-0014){ref-type="ref"}. Twelve fraction platforms were used in the current study. Following successful prefractionation, acetone precipitation, and protein quantification, 80 μg from each OFFGel fractions (*n* = 12) were subjected to reduction and alkylation, and digested with trypsin as described elsewhere [14](#pmic12160-bib-0014){ref-type="ref"}, [17](#pmic12160-bib-0017){ref-type="ref"}. Digested peptide solution was acidified using 90% formic acid to a final pH 3 and enriched using stage tip [18](#pmic12160-bib-0018){ref-type="ref"}, [19](#pmic12160-bib-0019){ref-type="ref"}. Efficiency of fractionation and digestion was confirmed as shown in Supporting Information 1. Chromatography of purified peptides was performed using Thermo Q‐Exactive and separation was applied using a binary gradient for 120 min with ACN as mobile phase. The precursor full MS scan ranged from 40--1200 *m/z*. Dynamic exclusion setting used were as follows: repeat count, 1; repeat duration, 30 s; exclusion list size, 450; and exclusion duration 60 s. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD002620 and 10.6019/PXD002620. In addition, all raw data (Thermo.RAW) are also available in the Peptide Atlas repository at <ftp://PASS00641:ZI6249ae@ftp.peptideatlas.org/> [20](#pmic12160-bib-0020){ref-type="ref"}.

Protein and peptide identification were searched by MASCOT in addition to ProluCID search engine implemented in the integrated proteomics pipeline; IP2 (<http://integratedproteomics.com/>, version 1.01) [14](#pmic12160-bib-0014){ref-type="ref"}. Tandem mass spectra were generated using RawExtract (version 1.9.9) and the MS/MS spectra were searched against updated UniProtKB/TrEMBL (Homo sapiens, 935 651 entries, released in February, 2015). The spectral search space included all fully and half‐tryptic peptide candidates within a 5‐ppm window surrounding the peptide candidate precursor mass. Carbamidomethylation (+57.02146) of cysteine was considered a static modification and oxidation at MHW (+15.995) as variable modification. Peptide candidates were filtered to 0.1% FDR and proteins candidates to 1% FDR using DTASelect [21](#pmic12160-bib-0021){ref-type="ref"} with a 10‐ppm window.

Our data analysis reported 2217 nonredundant protein representing ureter proteome (after omitting interfractional redundancy; see Fig. [1](#pmic12160-fig-0001){ref-type="fig"}). Full list of protein description is available in Supporting Information 2. Interestingly, when we compared the ureter dataset against urine [22](#pmic12160-bib-0022){ref-type="ref"}, urinary exosome [23](#pmic12160-bib-0023){ref-type="ref"}, [24](#pmic12160-bib-0024){ref-type="ref"}, and kidney databases [25](#pmic12160-bib-0025){ref-type="ref"}, [26](#pmic12160-bib-0026){ref-type="ref"}, [27](#pmic12160-bib-0027){ref-type="ref"}, [28](#pmic12160-bib-0028){ref-type="ref"}, [29](#pmic12160-bib-0029){ref-type="ref"}, result showed that 24.3% of the ureter annotated proteins (540 candidates) were detected in earlier urine database reports (see Fig. [2](#pmic12160-fig-0002){ref-type="fig"}A; zone E--H). Moreover, 21% of ureter proteins (467 proteins) were excreted as urinary exosomes (zone B, C, F, and G; details in Supporting Information 2). Validating these proteins in urine might allow more precise and supportive diagnostic determination of ureter disorders. Taken together, we conclude that over one‐third (33.8%; 751 proteins) of ureter proteome could be detected in urine as protein/polypeptide or in a vesicular exosomal form. Forty eight proteins were retained for ureter proteome (Fig. [2](#pmic12160-fig-0002){ref-type="fig"}A, zone A); These hits were further compared to urinary bladder and prostate database from HPA. We found that 21 protein candidates were either in a pending state, not found in HPA, or unique to ureter (Fig. [2](#pmic12160-fig-0002){ref-type="fig"}B, Supporting Information 3). Further investigations are required for these proteins. As illustrated in Fig. [3](#pmic12160-fig-0003){ref-type="fig"}, the Exponentially Modified Protein Abundance Index [30](#pmic12160-bib-0030){ref-type="ref"}, [31](#pmic12160-bib-0031){ref-type="ref"} (emPAI) values reflected the overwhelming abundance of these proteins in the urine. Consequently, these proteins may provide clues for monitoring the pathophysiology of the ureter. In conclusion, differentiating the precise origin of urinary proteins is still at its earliest stages and the full picture of urine biomarkers will be completed when we know not only the signature proteins of the UG tract tissues, but also plasma proteins as well. The ureter database generated in the current study will be initiative for further studies aimed at discriminating proteome of the UG tract and urine biomarkers precisely.
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![Venn diagrams of unique and shared ureter proteome with other databases. (A) Venn diagram of human ureter proteome overlapped with urinary, urinary exosomal, and kidney mass spectrometric databases. (B) Nonshared proteins in panel A (zone A) was further compared to human urinary bladder and prostate databases retrieved from HPA (based on immunohistochemistry) where 27 proteins were shared and 21 \[see Supporting Information 3\].](PMIC-16-80-g002){#pmic12160-fig-0002}
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The MS proteomics data in this paper have been deposited in the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository \[20\]: dataset identifier PXD002620.
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